How to buy iShares Core MSCI Total International (IXUS) ETF from India
IXUS is single-ticker exposure to the entire world ex-US — developed plus emerging, around 4,400 stocks at 0.07%. For an Indian investor it is a diversifier away from US concentration, not a starter holding.
Yes, an Indian resident can buy IXUS — legally, under the RBI's Liberalised Remittance Scheme (LRS). IXUS is iShares' Core MSCI Total International Stock ETF: ≈4,400 stocks across developed and emerging markets outside the US, one ticker, 0.07%. Think hard before buying it: you already live in an emerging market, and IXUS layers multi-currency FX on an INR base.
Live data via TradingView, in USD and possibly delayed. Shown for information only — not a quote, recommendation, or investment advice.
Wall Street analyst consensus — iShares Core MSCI Total International Stock ETF
Loading live consensus…
Live Wall Street analyst data via Finnhub. Refreshed at most once every 10 minutes. Analyst views change frequently; these are not Vested.blog recommendations. For information only — not investment advice.
Financials — iShares Core MSCI Total International Stock ETF
Historical financial data via TradingView. For Wall Street analyst consensus and price targets, see your broker, Yahoo Finance, or the company's investor-relations page. For information only.
The 30-second version
- Legal and simple. Buy IXUS via IBKR, Rovia, INDmoney, or Vested.
- One ticker, the world ex-US. Expense 0.07%. Tracks MSCI ACWI ex USA IMI — ≈4,400 stocks, developed plus emerging, outside the US.
- Dividends matter more here. Yield ≈3% — higher than US large-cap. 25% US withholding applies, reclaimable via DTAA and Form 67.
- India tax on gains: hold more than 24 months for 12.5% LTCG (no indexation); sell sooner and pay your slab rate. Section 112, not 112A.
- The trap most miss: directly-held IXUS is a US-situs asset — above $60,000, your estate faces up to 40% US estate tax with no treaty relief. A UCITS world-ex-US ETF dodges this.
Quick facts
| Can an Indian resident buy it? | Yes — fully legal under the LRS |
| Ticker / exchange | IXUS / NYSE Arca |
| Issuer | iShares (BlackRock) |
| Expense ratio | 0.07% per year |
| Holdings | ≈4,400 stocks (MSCI ACWI ex USA IMI), market-cap-weighted |
| Methodology | MSCI ACWI ex USA IMI Index, developed plus emerging, all-cap |
| Inception | October 2012 |
| Distribution | Quarterly dividend, yield around 3% |
| India tax on gains | 12.5% LTCG after 24 months; else your slab (Section 112) |
| Estate-tax risk | US-situs above $60k means up to 40%, no treaty relief |
| Annual compliance | Schedule FA disclosure, every year you hold |
How to buy it — 3 steps
- Open an account and finish KYC. Use IBKR for the widest access and best execution, Rovia for a combined RSU + LRS experience, or INDmoney / Vested for a simple India-funded flow. File your W-8BEN during onboarding — it drops US dividend withholding from 30% to the DTAA rate of 25%. New to this? See how to invest in US stocks from India.
- Fund it via the LRS. Remit from your Indian bank under the LRS (cap: $250,000 per FY). 20% TCS applies above ten lakh rupees in a year — a creditable prepayment, not a cost. See LRS explained and the LRS and TCS calculator. For the full compliance picture, see the LRS + TCS + Schedule FA trifecta.
- Place the order. IXUS trades in the mid-seventy-dollar range — a whole share fits any LRS budget, or buy a fractional rupee amount.
The tax that actually matters — dividends first
IXUS distributes ≈3% per year in four quarterly payouts — higher than the S&P 500, so dividend tax actually moves the after-tax return:
| Step | What happens | Rate |
|---|---|---|
| US withholding (with W-8BEN, DTAA) | Deducted by the broker before payout | 25% |
| India treatment | Dividend added to total income | Your slab rate |
| Relief | Claim the 25% US tax as foreign tax credit | Via Form 67 (TY 2025-26); Form 44 from TY 2026-27 |
Worked example. 100 shares at ≈$75 — position ≈$7,500. Annual distribution at 3% is $225. US withholds 25% = $56, you net $169. In India declare the full $225, pay at slab, claim $56 as FTC. At 30% slab, liability ≈$68 — net you pay another $12. Mechanics: dividend withholding and Form 67.
Capital gains — Section 112
On sale, gains fall under Section 112 — US-listed ETFs do not get the Section 112A treatment Indian-listed equity enjoys:
| Holding period | Treatment | Rate |
|---|---|---|
| 24 months or less | Short-term | Your slab rate (up to roughly 30% plus surcharge) |
| More than 24 months | Long-term | 12.5%, no indexation |
The gain is computed in rupees — but the underlying stocks are in a dozen currencies, so you are already running a multi-currency book before the rupee leg. Model with the US capital-gains calculator; rules in how US stocks are taxed in India and the India-US DTAA guide.
The $60,000 estate-tax trap
Directly-held IXUS is a US-situs asset — even though the underlying companies are not US-listed. Above $60,000 of US-situs assets at death, the estate faces up to 40% US estate tax, and the India-US treaty does not cover it. The fix (a UCITS world-ex-US ETF) is a choice made before the position is large. Detail: the $60,000 estate-tax trap.
What's actually in this ETF
IXUS holds ≈4,400 stocks — MSCI ACWI ex USA IMI constituents — float-adjusted market-cap-weighted, rebalanced quarterly. Developed plus emerging, all-cap (IMI extends below large-cap).
| Country | Approximate weight |
|---|---|
| Japan | ≈15% |
| United Kingdom | ≈10% |
| China | ≈8% |
| Canada | ≈8% |
| France | ≈7% |
| Switzerland | ≈6% |
| India | ≈5% |
| Germany | ≈5% |
| Australia | ≈5% |
| Korea, Taiwan, Netherlands, others | ≈31% combined |
The top 10 holdings — typically TSMC, ASML, Tencent, Samsung, Novo Nordisk, Nestle, Toyota, SAP, Alibaba, AstraZeneca — are ≈10% of the fund, less than half the S&P 500's ≈30%. Note the India line: an Indian buying IXUS pays ≈5% of every dollar to add more India on top of what they already own at home — that overlap is the main sizing question.
Alternatives — four legitimate routes to ex-US exposure
| Route | Expense | What you get | Notes for an Indian investor |
|---|---|---|---|
| IXUS (US-listed, iShares) | 0.07% | Developed + EM ex-US in one ticker | Default single-line ex-US holding |
| VXUS (US-listed, Vanguard) | 0.05% | Developed + EM ex-US in one ticker | Vanguard sibling — essentially identical exposure |
| VEA + VWO (DIY split) | 0.05% / 0.07% | Developed (VEA) and EM (VWO) separately | Lets you over- or underweight EM deliberately |
| UCITS ex-US ETF (Ireland) | ≈0.20% | Developed + EM ex-US, Ireland-domiciled | Avoids 25% US WHT and the $60k estate trap |
IXUS vs VXUS is a wash — same broad index family, expense within a couple of basis points; going to the other is reasonable issuer-diversification. VEA + VWO is the route to control EM weight directly (an Indian investor often wants less EM, not more). The UCITS ex-US ETF is the structural answer at size — avoids the 25% dividend WHT and the $60k estate trap. Indian international funds are limited and expensive. See best US ETFs for Indian investors and US ETFs for Indians.
Our take
Verdict: HOLD — IXUS is single-ticker exposure to the world ex-US, useful as a diversifier against heavy US concentration but not a starter holding for an Indian investor.
- The case for. Maximum ex-US diversification in one line — developed plus emerging, ≈4,400 stocks, top-10 under half the S&P 500's, at 0.07%. If you are heavily tilted to US large-cap, IXUS is the cleanest way to reduce that.
- The case against, for an Indian investor. You already live in EM India — adding ≈5% India inside IXUS plus other EM is doubling down on EM, not diversifying. You are also running a multi-currency book: holdings in yen, euro, pound, yuan, won, translated to USD and then INR. Layered FX, not hedged. The ex-US-versus-US record of the last fifteen years is what it is.
- Where it fits. A diversifier sleeve once a US core is in place. Not a first US ETF. If estate-tax exposure binds, a UCITS world-ex-US ETF; if you want EM control, VEA plus VWO.
Compliance note. Vested.blog is not a SEBI-registered Research Analyst. The above is an editorial opinion for educational illustration only — not investment advice and not a regulated stock recommendation. Vested.blog is published by Rovia; the publisher and its affiliates may hold positions in stocks discussed. Make your own decisions or consult a SEBI-registered advisor.
Risks to size for
- Lower expected growth than US large-cap. Ex-US has trailed the S&P 500 for most of the last fifteen years. The case for IXUS is mean reversion, not momentum.
- Multi-layer FX. Stocks in a dozen currencies, translated to USD inside the fund, then to INR for you — three currency legs, not one. See the rupee-dollar effect.
- EM regulatory and political risk. China is the largest EM weight, with policy and listing risk that has hit ex-US funds before. India inside IXUS overlaps with your home portfolio.
- Demographics. Japan and much of developed Europe sit in IXUS with structural population headwinds the index does not adjust for.
Two things people forget
- Schedule FA: disclose IXUS in Schedule FA every year you hold it — even at a loss. Non-disclosure carries Black Money Act penalties. Use the Schedule FA helper. See the Schedule FA disclosure guide for full details.
- Form 67 (Form 44 from TY 2026-27): file it to claim the 25% US dividend withholding as foreign tax credit. IXUS's ≈3% yield makes this paperwork worth more than on a US large-cap ETF — skip it and you have paid tax twice on a meaningful dividend stream.
Bottom line
Buying IXUS from India is easy and legal. Whether you want it is the question: a higher-yield US-listed ETF (25% WHT plus Form 67), Section 112 on gains (12.5% after 24 months, not 112A), US-situs with the $60k estate trap at size — on top of multi-currency exposure and an India overlap with your home portfolio. The 0.07% expense and one-ticker breadth make it the cleanest single-line ex-US diversifier; VXUS is essentially identical; a UCITS world-ex-US ETF is the structural answer at size. For most Indian investors, IXUS belongs on a diversifier sleeve after the US core, not before. Start at the US investing hub.
Related stocks and ETFs to consider
Indian investors researching IXUS often also look at:
- VOO from India — Vanguard S&P 500 ETF — the standard US large-cap index
- QQQ from India — Nasdaq-100 ETF with heavy tech weighting
- VTI from India — Vanguard Total Stock Market ETF — all US stocks
- Best US ETFs for Indian investors — our full ETF guide
This article is general information, not personalised investment, tax, or legal advice. Rules, rates, and thresholds described here are as of 2026 and can change; verify the current position and consult a qualified advisor before acting.
Run your own numbers
Try the calculators that match this post
Frequently asked questions
▾
▾
▾
▾
▾
Found this useful? Share it.
Help another Indian working with US RSUs or LRS not get blindsided by this stuff.
About the author

Co-Founder & Chief Executive Officer, Rovia
CFA charterholder with 10+ years across hedge funds and NRI fintech. Covers RSU taxation, equity comp, and cross-border investing for Indian residents. Ex-JP Morgan, Makrana Capital, Zolve.
More about Shivang →Get more like this in your inbox
One practical post a week on US investing & RSU strategy.
Comments
No comments yet. Be the first.
Keep reading
How to buy Vanguard FTSE Developed Markets (VEA) ETF from India
VEA is Vanguard's developed-markets-ex-US ETF — roughly 4,000 stocks across Europe, Japan, Canada and Australia at a 0.05% expense ratio. For an Indian investor it is a diversifier, not a starter holding, with multi-currency FX and the US estate trap still in play.
How to buy Vanguard Total International Stock (VXUS) ETF from India
VXUS is Vanguard's total ex-US equity ETF — developed and emerging markets in one ticker at 0.05%. The Vanguard sibling of IXUS, broader index, same $60k estate trap and multi-layer FX caveats for an Indian investor.
How to buy Vanguard Total Stock Market (VTI) ETF from India
VTI is Vanguard's whole-market US ETF — 3,500+ stocks spanning large, mid, and small caps at a 0.03% expense ratio, bought legally under the LRS. The trade-off versus VOO is broader diversification at the cost of slightly higher distributions.